FDA Approves Phase 2 Trial Modification for Abion's Novel Lung Cancer Combination Therapy
The FDA has approved modifications to the Phase 2 clinical trial for vabametkib, Abion's c-MET targeted anticancer drug, in combination with lazertinib for non-small cell lung cancer patients. The trial will evaluate this novel combination therapy in patients who have developed resistance to EGFR-targeted treatments, addressing a significant unmet need in NSCLC treatment.
© Copyright 2025. All Rights Reserved by MedPath